ADAR1 CAPITAL MANAGEMENT LLC
Q3 2026 Form 13-F

AUSTIN, TEXAS
CIK 0001940272 · CRD 299694 · SEC-registered investment adviser
$2.3B Reported Value Total

ADAR1 CAPITAL MANAGEMENT, LLC reports 8 total accounts under management (AUM). There are 8 discretionary accounts valued at $1,675,126,109, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
2 funds · $1.3B gross asset value
Hedge Fund: $1.3B
Source: Form ADV filed 2026-03-31
Reported value
$2.3B
Quarter over quarter
-6.9%
Holdings
261
Top-10 concentration
38.7%

Key People

Form ADV owners & control persons
Daniel Pawel Schneeberger
MANAGING PARTNER
Stuart Knox Graham
COO
Stephen Thomas Scipione
HEAD OF OPERATIONS, CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $2.3B
Positions 261
Change in reported value +7.5%
New positions 43
Exited positions 42
Position turnover 28.1%
Top-10 concentration 38.7%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
261 $2.3B
Q2 2026 13F
Filed Aug 14, 2026
262 $2.2B
Q1 2026 13F
Filed May 18, 2026
290 $1.7B
Q4 2025 13F
Filed Feb 17, 2026
249 $1.4B
Q3 2025 13F
Filed Nov 14, 2025
197 $1.1B
Q2 2025 13F
Filed Aug 14, 2025
199 $652.1M
Q1 2025 13F
Filed May 15, 2025
192 $538.7M
Q4 2024 13F
Filed Feb 13, 2025
195 $500.4M
Q3 2024 13F
Filed Nov 14, 2024
258 $614.9M
Q2 2024 13F
Filed Aug 13, 2024
245 $529.7M
Q1 2024 13F
Filed May 15, 2024
239 $440.8M
Q4 2023 13F
Filed Feb 14, 2024
150 $279.8M

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 ABVX ABIVAX SA $203.1M 8.65%
2 SPY STATE STR SPDR S&P 500 ETF T $135.5M 5.77%
3 PTGX PROTAGONIST THERAPEUTICS INC $134.0M 5.71%
4 ROIV ROIVANT SCIENCES LTD $112.6M 4.79%
5 ZLAB ZAI LAB LTD $89.1M 3.79%
6 IMVT IMMUNOVANT INC $71.5M 3.04%
7 XENE XENON PHARMACEUTICALS INC $43.2M 1.84%
8 DNLI DENALI THERAPEUTICS INC $42.8M 1.82%
9 BOXX EA SERIES TRUST $39.9M 1.7%
10 SEPN SEPTERNA INC $38.1M 1.62%
11 AGIO AGIOS PHARMACEUTICALS INC $37.9M 1.61%
12 AURA AURA BIOSCIENCES INC $33.8M 1.44%
13 VKTX VIKING THERAPEUTICS INC $33.7M 1.44%
14 CYTK CYTOKINETICS INC $30.4M 1.29%
15 INSM INSMED INC $26.2M 1.12%
16 FRNM FREENOME INC $25.9M 1.1%
17 CLDX CELLDEX THERAPEUTICS INC NEW $25.9M 1.1%
18 AVR ANTERIS TECHNOLOGIES GLOBAL $25.2M 1.07%
19 BBIO BRIDGEBIO PHARMA INC $25.0M 1.06%
20 PRAX PRAXIS PRECISION MEDICINES I $24.7M 1.05%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings